CECILY BOSMA: Open Payments
NPI 1063468338 · SANTA BARBARA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$779 in 37 payments from 9 companies in 2025. Trend: 2023 $436 · 2024 $617 · 2025 $779
Food & beverage: $779
| Company | Payments | Amount |
|---|---|---|
| Abbott Laboratories | 14 | $183 |
| Xeris Pharmaceuticals, Inc. | 7 | $159 |
| Tandem Diabetes Care, Inc. | 2 | $123 |
| Sequel Med Tech, LLC | 5 | $102 |
| GlaxoSmithKline, LLC. | 3 | $71 |
| Antares Pharma, Inc. | 2 | $58 |
| SANOFI-AVENTIS U.S. LLC | 2 | $39 |
| BETA BIONICS, INC. | 1 | $29 |
| Dexcom, Inc. | 1 | $16 |
Products named: FREESTYLE LIBRE 3, RECORLEV, t:slim X2 Insulin Pump with Control-IQ, TWIIST, BENLYSTA, XYOSTED, TZIELD, iLet Bionic Pancreas.
Industry payments across CA — which companies pay providers there.
